STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart Failure | MicrobiomeTrials← Back to trialsNCT07631156
STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart Failure
RecruitingPHASE4INTERVENTIONAL
Trial Details
Start: 2026-06-30Est. Completion: 2029-06-30
Enrollment target: 80 participants Locations- Keimyung University Dongsan Hospital, Daegu, Daegu, South Korea
- Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea
- Ajou University Hospital, Suwon, Gyeonggi-do, South Korea
- Pusan National University Yangsan Hospital, Yangsan, Gyeongsangnam-do, South Korea
- Korea University Anam Hospital, Seoul, Seoul, South Korea
Other microbiome trials you might be interested in
Mitral Valve ProlapseMitral Regurgitation
Mitral regurgitation (MR) is the second most frequent valvular heart disease and the second most frequent indication for…
Milan, ItalyEst. completion Jun 1, 2029
Heart Failure With Preserved Ejection Fraction
Met-PEF will be a randomized, double-blind, placebo-controlled trial to examine the effects of 20 weeks of 1500 mg/day o…
Charlotte, United StatesCompleted Dec 18, 2025
In Cheol Kim, Professor
Phase 3
Recruiting
This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF…
Mobile, United StatesEst. completion Feb 4, 2029